Newsletter | April 29, 2024

04.29.24 -- How To Determine Country Feasibility For CGT Clinical Trials

CLINICAL SITES

How To Determine Country Feasibility For Cell And Gene Therapy Clinical Trials

Guest Column | By Jessica Cordes, Clinical Excellence GmbH

Learn how to choose the right location — globally — for your next cell and gene therapy clinical trial.

Bayer's Solution To Streamline Investigator Payments Worldwide

White Paper | IQVIA Technologies

Year after year, slow and unpredictable investigator payments continue to be a top complaint from clinical study sites. See what's happening in Bayer's Automated Site Payment Invoice Resolution project.

Q&A About Bristol Myers Squibb’s Consolidated Site Payments Strategy

Q&A | IQVIA Technologies

How do payment systems affect site-sponsor relationships? George Kourtsounis of Bristol Myers Squibb and Casey Orvin of CenExel Clinical Research lend their expertise to this question and more.

PATIENT CENTRICITY

Medical Director, PI, And Educator: A 3D Perspective On Diverse Patient Enrollment

Guest Column | A conversation with Monique Gary, Grand View Health Cancer Program

Based on past experiences, Monique Gary, DO, MSc, FACS, FSSO, discusses diverse patient enrollment as well as ways in which sponsors, sites, advocates, and others can better serve minority and LGBTQ+ trial participants.

Optimizing The Rare Disease Patient Experience

Article | Scout

Pam Cusick of Rare Patient Voice provides valuable insights into rare disease participant needs and ways to optimize clinical trials for enrollment and retention.

Solutions To Clinical Trial Travel

Article | Elligo Health Research

Read why the increase in travel distance, time, and frequency suggests patient travel is a bigger barrier to patient recruitment and retention than the industry previously thought.

Auto-Injectors: A Revolutionary Leap In Drug Delivery

Article | By Bill Welch, PCI Pharma Services

Explore how the widespread adoption of auto-injectors is transforming the biopharmaceutical industry's approach to drug delivery, offering precise dosing, patient adherence, and safety.

PATIENT RECRUITMENT

$100M In Funding Helps, But What Can Really Be Done About Trial Diversity?

Guest Column | By Monique Gary, Grand View Health cancer program 

Monique Gary, medical director of the Grand View Health cancer program, lists three steps to take right now to improve clinical trial patient diversity.

Retention Improved In A Pompe Disease Clinical Trial

Case Study | PCM Trials

Uncover the ways one double-blind, randomized Phase 3 study was able to boost the participant’s overall adherence to the protocol and increase their willingness to continue with the trial.

CHOOSE YOUR OWN ADVENTURE

You're receiving the Monday edition of the Clinical Leader newsletter, focusing on Clinical Sites, Patient Centricity, and Patient Recruitment. To make changes to your newsletter selections, update your topic preferences.

  • Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
  • Clinical Trial Technology (Tuesday)
  • Decentralized Trials | Trial Management (Wednesday)
  • Outsourcing Models | Regulatory & Compliance (Thursday)
  • Clinical Data Management & Analytics | Trial Monitoring (Friday)

Learn more about our personalized newsletters here.

Connect With Clinical Leader: